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Abstract
Background: Increased lipoprotein(a) [Lp(a)] levels are associated with
atherosclerotic cardiovascular disease. Studies of dietary interventions on changes
in Lp(a) are sparse. We aimed to compare the effects of three healthy dietary
interventions differing in macronutrient content on Lp(a) concentration.
Methods: Secondary analysis of a randomized, 3-period crossover feeding study
including 155 (89 blacks; 66 whites) individuals. Participants were given DASH-
type healthy diets rich in carbohydrates [Carb], in protein [Prot] or in unsaturated fat
[Unsat Fat] for 6 weeks each. Plasma Lp(a) concentration was assessed at
baseline and after each diet.
Results: Compared to baseline, all interventional diets increased mean Lp(a) by 2
to 5 mg/dl. Unsat Fat increased Lp(a) less than Prot with a difference of 1.0 mg/dl
(95% CI, 20.5, 2.5; p50.196) in whites and 3.7 mg/dl (95% CI, 2.4, 5.0; p,0.001)
in blacks (p-value between races50.008); Unsat Fat increased Lp(a) less than
Carb with a difference of 20.6 mg/dl, 95% CI, 22.1, 0.9; p50.441) in whites and
21.5 mg/dl (95% CI, 20.2, 22.8; p50.021) in blacks (p-value between
races50.354). Prot increased Lp(a) more than Carb with a difference of 0.4 mg/dl
(95% CI, 21.1, 1.9; p50.597) in whites and 2.2 mg/dl (95%CI, 0.9, 3.5; p50.001) in
blacks (p-value between races50.082).
Conclusion: Diets high in unsaturated fat increased Lp(a) levels less than diets
rich in carbohydrate or protein with greater changes in blacks than whites. Our
results suggest that substitutions with dietary mono- and polyunsaturated fatty
acids in healthy diets may be preferable over protein or carbohydrates with regards
to Lp(a).
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Introduction
Lipoprotein(a) [Lp(a)] is a plasma lipoprotein consisting of a cholesterol-rich
LDL-like particle having one molecule of apolipoprotein B100 and an additional
protein, apolipoprotein(a), attached to apoB via a disulfide bond [1,2].
Epidemiologic studies have shown that elevated Lp(a) concentration is an
independent risk factor for CVD attributed to its similarity to LDL and its
structural homology of apolipoprotein(a) with plasminogen resulting in impaired
thrombolysis [3,4,5,6,7]. Moreover, because Lp(a) spends a long time in
circulation, i.e. 3–5 days, it has been argued that apo(a) impairs the removal of an
atherogenic LDL-like particle from plasma which thereby increases its time in
circulation for interactions with the vascular wall [8,9].
Lp(a) concentration is regarded as largely genetically determined
[10,11,12,13]. Levels of Lp(a) are similar in men and women but vary among
races with non-Hispanic whites having the lowest and blacks the highest [14].
Pharmacological therapies such as niacin and oral estrogens can lower Lp(a) level
[9,15], but investigations examining the effect of various dietary compositions on
Lp(a) are sparse [16,17]. So far, it has been reported that Lp(a) levels increase as a
consequence of reducing and replacing dietary fat intake, and in particular
saturated fat, with carbohydrates [16,17]. However, to our knowledge no
investigation has evaluated the influence of mono- or polyunsaturated fat
compared to carbohydrates on Lp(a) levels in the context of a healthy dietary
pattern. Moreover, data on the effect of dietary protein on Lp(a) are controversial
[18,19,20,21,22].
In this report, we systematically compared the effects of three healthy diets
differing in their macronutrient content on Lp(a) levels using a randomized cross-
over design in an isocaloric nutritional setting. The primary outcome was the
change in Lp(a) during a protein- or unsaturated fat-rich diet compared to a
carbohydrate-rich diet. Because blacks have higher Lp(a) concentrations than
whites, we investigated secondary racial differences in Lp(a) response to changing
macronutrient compositions.
Methods
Study population
This is a secondary analysis of the ‘Optimal Macronutrient Intake Trial to Prevent
Heart Disease’ (Omni Heart). The rationale and main results of the Omni Heart
Trial have been published [23,24]. In brief, 164 generally healthy participants
were recruited from the population of the greater Baltimore, MD, and Boston,
MA, areas. Participants were aged 30 years or older with blood pressure values
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BP of 80–99 mm Hg). Participants with fasting LDL cholesterol exceeding
220 mg/dL, or triglycerides exceeding 750 mg/dL were not eligible for this trial.
Race was self-identified via questionnaire. For this analysis, we only included
black or white individuals. The Omni Heart trial aimed to recruit approximately
50% blacks as this group suffers from a high burden of hypertension and CVD.
The study protocol was approved by the Institutional Review Boards at all
affiliated institutions (Johns Hopkins University, Brigham & Women’s Hospital,
and the Harvard School of Public Health). Each participant provided written
informed consent.
Dietary Interventions
The Omni Heart Trial used a randomized, 3-period crossover design of controlled
feeding to compare the effects of macronutrients on blood pressure and plasma
lipids [23,24]. Dietary interventions took place from April 2003 to June 2005.
Three diets were tested – one diet emphasized carbohydrate [Carb], a second diet
emphasized protein [Prot], and a third diet emphasized unsaturated fat [Unsat
Fat]. A detailed description of these three diets is summarized in Table 1. All three
diets were based on the ‘Dietary Approaches to Stop Hypertension’ (DASH) diet
[20,24,25]. Each diet was reduced in saturated fat, cholesterol, and sodium, and
rich in fruits, vegetables, fish, potassium, and other minerals at recommended
levels. Protein mostly came from plants (legumes, grains, nuts, and seeds), but
also included meat, poultry, egg product substitutes, dairy products and some soy
products, although the amount was low (on average 7.3 g per day). The
unsaturated fat diet emphasized mono- and polyunsaturated fat and included
olive, canola, and safflower oils, as well as a variety of nuts and seeds, to meet its
target fatty acid distributions. The type of carbohydrate as indicated by the total
glycemic index was similar in all diets. All diets were held isocaloric.
After a 6-day run-in period, in which participants ate 2 days of meals from each
study diet, participants were randomly assigned to 1 of 6 sequences of these
feeding protocols [23,24]. Each feeding period lasted 6 weeks. Throughout the
feeding periods, participants were provided with all nutrition prepared in research
kitchens. Meals were consumed on-site on weekdays. Weekend meals were
consumed off-site. Participants were instructed to drink no more than 3
caffeinated beverage and no more than 2 alcoholic beverages per day. Trial
participants were further asked not to change the level of exercise. Weight was
measured each weekday and was kept stable by adjusting caloric levels, by adding
100-kcal cookies with the nutrient content of the assigned diet, or both. During
controlled feeding, participants kept a diary recording compliance with study
foods and consumption of non-study foods. According to these records,
adherence was high i.e. all study food was consumed and no additional non-study
food was eaten on 95 to 96% of person-days for each diet [24].
A washout period of 2 to 4 weeks separated the feeding periods. During the
washout, participants ate their own food (self-selected diet) [23,24]. The duration
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following scientific and practical considerations [23]. As the biological half-life of
Lp(a) is estimated to be approximately 3 to 4 days [8], a wash out period of 2
weeks for this secondary analysis of the Omni Heart Trial was considered
sufficient.
The total study population of this secondary analysis was 155 individuals
(Table 2). The sample size for each of the three comparisons was as follows Carb
vs Unsat Fat: n5151/Carb vs Prot: n5151/Unsat Fat vs Prot: n5150.
Laboratory measurements
Details of laboratory measurements have been published previously [23,24,26].
Briefly, blood samples of each participant were collected at baseline and after each
of the three 6-week diet periods. Blood was drawn after a 12 h overnight fast into
EDTA tubes. Plasma was separated by centrifugation at 1.500 rpm for 15 min at
4˚C and immediately frozen at 270˚C. The resulting serum was then shipped to
the Core Laboratory for Clinical Studies (CLCS) of Washington University
Medical School, St. Louis, Mo. Each participant’s 4 samples were analyzed in the
same batch in random order to reduce analytic variation. Batches consisted of
samples of 5 or 9 participants, and analyses were completed within 5 days. All
laboratory staff were blinded to the diet sequences of the study participants. Lp(a)
was measured using an enhanced in-vitro diagnostic immunoturbidimetric assay
for the quantitative determination of Lp(a) in serum (Wako Diagnostics: Lp(a)
autokit). The assay utilized an anti-human Lp(a) antibody that does not cross-
react with plasminogen or apoB and yields an insoluble aggregate that causes
increased turbidity. The degree of turbidity was detected optically and was
proportional to the amount of Lp(a) in the sample. Commercially available
standards were used (Wako Chemicals, USA). All measurements were carried out
at the Core Laboratory for Clinical Studies (CLCS) of Washington University
Medical School, St. Louis, Mo.
Table 1. Baseline Intake and Nutrient Targets of Omni Heart Diets.
Nutrient Targets of Omni Heart Diets
Baseline (¡ SD) Carb Prot Unsat Fat
Carbohydrate (% of energy) 50¡95 8 4 8 4 8
Fat (% of energy) 31¡62 7 2 7 3 7
Saturated 11¡36 6 6
Monounsaturated 13¡31 3 1 3 2 1
Polyunsaturated 7¡28 8 1 0
Protein (% of energy) 17¡41 5 2 5 1 5
Meat 12¡4 5.5 9 5.5
Plant and Dairy 5¡2 9.5 16 9.5
doi:10.1371/journal.pone.0114859.t001
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The primary outcome for this secondary analysis of the Omni heart trial was
change in Lp(a) during the Prot or Unsat diets compared to the Carb diet.
Secondary, the effects of the intervention diets on Lp(a) in blacks compared to
whites was a major aim. To assess changes from baseline and interdietary
differences in Lp(a) in the overall study population as well as the effect
modification by race we calculated mean differences (95% CI) using generalized
estimating equations with an exchangeable correlation matrix accounting for
study site and intervention order (Table 3). Similarly, generalized estimation
equation models with interaction terms for a priori specified variables were
calculated to estimate the respective effect sizes and effect modification (gender),
as appropriate (S1 Table). Models without (Table 3 and S1 Table) and with (S2
Table and S3 Table) adjustment for baseline Lp(a) levels were calculated to
evaluate the importance of baseline Lp(a) for the observed Lp(a) effect size after
Table 2. Participant Characteristics at baseline
1.
All Race p-value
Black White
n 155 89 66 -
Female (%) 46 56 32 -
Age (y) 54 52 56 0.046
¡11 ¡11 ¡10
BMI (kg/m2) 30 31 29 0.016
6 ¡6 ¡6
Homa Index 2.4 2.6 2.3 0.506
¡2.3 ¡2.0 ¡2.8
Lp(a) (mg/dl) 26.1 31.9 18.3 ,0.001
¡23.0 ¡22.0 ¡22.2
Triglycerides (mg/dl) 132.1 117.7 151.5 0.019
¡88.8 ¡88.0 ¡86.9
Total Chol (mg/dl) 203.7 200.0 211.6 0.029
¡35.7 ¡32.6 ¡38.5
LDL-C (mg/dl) 129.2 126.1 134.5 0.11
¡32.4 ¡31.4 ¡32.9
HDl-C (mg/dl) 50.0 51.3 47.8 0.184
¡16.1 ¡17.9 ¡13.2
Apo B (mg/dl) 84.2 80.0 90.1 0.018
¡26.2 ¡21.5 ¡30.9
Apo C-III (mg/dl) 12.7 10.7 15.4 ,0.001
¡8.0 ¡5.8 ¡9.7
Apo E (mg/dl) 7.5 7.7 7.2 0.333
¡2.8 ¡2.9 ¡2.7
1HOMA, homeostasis model assessment; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; Apo, apolipoprotein. P values were derived from Student’s t
test comparing the different races. Values are unadjusted means ¡ SD.
doi:10.1371/journal.pone.0114859.t002
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multiple comparisons. All analyses were conducted using STATA 11.0
Results
Participants
The characteristics of included participants at baseline examination are shown in
total and by race in Table 2. Among 155 individuals in this analysis, 89 were black
and 66 whites. Those belonging to the black racial group were more likely to be
female, to be younger and have a higher BMI. Total apo C-III, apo B, cholesterol
and triglyceride levels were significantly higher in whites compared to blacks. No
difference in HOMA index was detected between races. The drop-out rate in the
Omni Heart Trial was low for both races and distributed evenly across the 3 diets
as reported previously [24,26]. During the feeding program, mean body weight
decreased on average from baseline by 1 kg, and this change occurred equally
across all 3 diets in both blacks and whites [24,26].
Changes in Lp(a) concentration from baseline
On self-selected diet at baseline mean Lp(a) was 26.1 mg/dl (95% CI, 22.5, 29.8)
in the total study population, 18.3 mg/dl (95% CI, 12.9, 23.8) in whites and
31.9 mg/dl (95% CI, 27.3, 36.5) in blacks. Compared with baseline all dietary
interventions increased mean Lp(a) levels in the total population and across
whites and blacks (Table 3/Fig. 1). Largest Lp(a) increases were observed after the
Prot diet (4.7 mg/dl; 95% CI, 3.7, 5.7; p,0.001) followed by the Carb (3.2 mg/dl;
95% CI, 2.2, 4.2; p,0.001) and Unsat Fat diet (2.1 mg/dl; 95% CI, 1.1, 3.1;
p,0.001) in the total study population. After the Prot diet blacks responded with
significantly larger Lp(a) increases from baseline than white participants (6.2 vs.
Table 3. Lp(a) concentration (mg/dl) with diet by ethnicity: Changes from baseline and differences between diets reported as mean [95% CI].
All Whites Blacks
D
mean [95%CI] p-value
D
mean [95%CI]
p-
value
D
mean [95%CI] p-value
p-value
between
races
Change from base-
line
Carb 3.2 (2.2, 4.2) ,0.001 2.2 (0.7, 3.7) 0.004 4.0 (2.7, 5.3) ,0.001 0.067
Unsat 2.1 (1.1, 3.1) ,0.001 1.6 (0.1, 3.1) 0.038 2.5 (1.2, 3.8) ,0.001 0.372
Prot 4.7 (3.7, 5.7) ,0.001 2.6 (1.1, 4.1) 0.001 6.2 (4.9, 7.5) ,0.001 ,0.001
Difference between
study diets
[Carb] to
[Unsat Fat]
21.1 (20.1,
22.1)
0.026 20.6 (22.1, 0.9) 0.441 21.5 (20.2,
22.8)
0.021 0.354
[Carb] to
[Prot]
1.4 (0.4, 2.4) 0.005 0.4 (21.1, 1.9) 0.597 2.2 (0.9, 3.5) 0.001 0.082
[Unsat Fat]
to [Prot]
2.5 (1.5, 3.5) ,0.001 1.0 (20.5, 2.5) 0.196 3.7 (2.4, 5.0) ,0.001 0.008
doi:10.1371/journal.pone.0114859.t003
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between whites and blacks after a Carb (2.2 vs. 4.0 mg/dl; p-value between
races50.067) or an Unsat Fat diet (1.6 vs. 2.5 mg/dl; p-value between
races50.372) were not significantly different.
Changes in Lp(a) concentration between interventional diets
Compared with baseline the Unsat Fat diet increased mean Lp(a) levels less than
the Carb diet (21.1 mg/dl; 95% CI, 20.1, 22.1; p50.026) while the Prot diet
increased Lp(a) concentration more than the Carb diet (1.4 mg/dl; 95% CI, 0.4,
2.4; p50.005) and more than the Unsat Fat diet (2.5 mg/dl; 95% CI, 1.5, 3.5;
p,0.001). Among races Unsat Fat increased Lp(a) less than Carb with a difference
of 20.6 mg/dl, 95% CI, 22.1, 0.9; p50.441) in whites and 21.5 mg/dl (95% CI,
20.2, 22.8; p50.021) in blacks (p-value between races50.354) (Table 3/Fig. 2).
Compared with baseline the Prot diet increased mean Lp(a) by 1.0 mg/dl (95%
CI, 20.5, 2.5; p50.196) more than the Unsat Fat diet in whites and by 3.7 mg/dl
(95% CI, 2.4, 5.0; p,0.001) in blacks (p-value between races50.008). Among
races Prot increased Lp(a) more than Carb with a difference of 0.4 mg/dl (95%
CI, 21.1, 1.9; p50.597) in whites and 2.2 mg/dl (95%CI, 0.9, 3.5; p50.001) in
blacks (p-value between races50.082) (Table 3/Fig. 2).
We also examined gender differences in Lp(a) as a response to dietary changes
(S1 Table). After consumption of a Carb diet female study participants exhibited
significantly larger increases in Lp(a) compared to men (4.2 vs. 2.5 mg/dl;
p50.087) but not after the Unsat Fat (2.4 vs. 1.9 mg/dl, p50.640) or the Prot (5.1
vs. 4.2 mg/dl; p50.370) diet. Overall, no significant effect modification by gender
was observed (p50.368). Additional analyses on Lp(a) changes by race after
dietary interventions and on effect modification by gender that adjusted for
Fig. 1. Mean [95% CI] changes in plasma Lp(a) from baseline by diet in all participants (Fig. 1a) and in blacks and whites (Fig. 1b) are shown. P-
values for differences to baseline (Fig. 1a) and between races (Fig. 1b) are displayed. All interventions increased Lp(a). Between races, study diets
increased Lp(a) in blacks more than in whites with significant differences after the Prot diet.
doi:10.1371/journal.pone.0114859.g001
Healthy Dietary Interventions and Lipoprotein (a)
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and S3 Table; S1 Figure and S2 Figure).
Discussion
Healthy dietary interventions based on the DASH diet that emphasize
carbohydrate, protein, or unsaturated fat have been shown to reduce atherogenic
lipids and lipoproteins with diets rich in mono- or polyunsaturated fat or protein
resulting in highest benefits [24]. Although Lp(a) is largely regarded as genetically
determined [10,12,13], in our study DASH-type diets differing in macronutrient
content increased Lp(a) compared to baseline. Among dietary interventions the
Unsat Fat diet increased Lp(a) plasma levels less than the Carb and Prot diet.
Blacks tended to respond with greater Lp(a) changes to dietary interventions
compared to whites. Gender did not modify the effect of diet on Lp(a)
concentrations.
The mechanisms by which macronutrient compositions influence Lp(a) levels
are unknown. Previously, in the Delta study Ginsberg et al. reported increases of
Lp(a) levels as total fat and in particular saturated fat intake were reduced and
replaced by carbohydrates with intake of mono- and polyunsaturated fat or
protein held constant [16]. Similarly, Shin et al. observed increases in Lp(a) after a
high-fat low carbohydrate diet as compared to low-fat high carbohydrate study
[17]. These data suggest that carbohydrate increases Lp(a) when it replaces either
saturated or unsaturated fats [16,17]. So far, limited evidence in humans is
available comparing the effects on Lp(a) of saturated with unsaturated fats which
indicate a slight increase in Lp(a) when replacing saturated fat with
Fig. 2. Mean [95% CI] changes in plasma Lp(a) between study diets in all participants (Fig. 2a) and in blacks and whites (Fig. 2b). P-values for
differences between diets in all participants (Fig. 2a) and between blacks and whites (Fig. 2b) are displayed. Unsat Fat reduced Lp(a) compared to Proto r
Carb. Blacks showed greater Lp(a) reductions when changing from Prot to Unsat Fat as compared to whites.
doi:10.1371/journal.pone.0114859.g002
Healthy Dietary Interventions and Lipoprotein (a)
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polyunsaturated dietary fatty acids lowered Lp(a) concentrations compared to the
saturated fatty acids, lauric and myristic acids [28,29]. Specifically monkeys on a
monounsaturated diet had decreased hepatic apo(a) messenger RNA abundance
resulting in a decreased hepatic apo(a) transcription and decreased apo(a)
production [28,29]. On the other hand, Lp(a) has been observed to rise with
increased intake of trans-fatty acids [16,30,31]. In the Omni Heart trial trans-
fatty acids were avoided in all intervention diets as these are known to have
deleterious effect on cardiovascular health [25,26].
Among dietary factors potentially altering Lp(a), some studies found soy
protein and isoflavones to increase plasma Lp(a) [20,22] while others did not
confirm this [18,19,21,32]. The Prot diet consumed in our study contained little
soy protein. The observed effect of protein on Lp(a) is therefore unlikely to be
caused by soy and isoflavones but rather by other unknown reasons. Principally,
dietary protein intake may affect apo(a) production rates as well as Lp(a)
assembly rates, and catabolism rates. As plasma Lp(a) concentrations have been
shown to be primarily controlled by the rate of synthesis rather than by the rate of
clearance [8,33,34], dietary proteins may likely lead to an increase in Lp(a)
production. Studies on the relationship of hormone treatment and drugs such as
niacin with Lp(a) concentration support this notion [34]. Estrogen treatment of
postmenopausal women reduces Lp(a) production and it thereby lowers plasma
Lp(a) while it does not alter the catabolic rate of Lp(a) [9]. Similarly, niacin does
not affect the catabolism of Lp(a) but decreases its synthetic rate and consequently
lowers plasma Lp(a) levels [15]. Despite the rise in Lp(a) associated with the
intake of a high protein compared to a high unsaturated fat DASH-type diet,
given the beneficial effects of this dietary pattern on other plasma lipids such as
LDL and on blood pressure, the healthy consequences may counteract and
outweigh the potentially undesirable effects of an elevated Lp(a) concentration.
Nonetheless, it is another aspect to consider when comparing Prot to Unsat Fat in
the context of evaluating and analyzing the physiological changes of a healthy
dietary pattern [24].
Blacks have higher average Lp(a) plasma concentrations than do whites
[10,12,13]. Differences in dietary habits may explain only part of the racial
difference in Lp(a). When consuming their usual diets at baseline, blacks reported
consuming approximately 4% more calories from carbohydrate but 1 to 2% less
from saturated or unsaturated fat than did whites [23,24,26]. Among ethnicities
Lp(a) response to various dietary strategies is largely unknown [16]. Under
controlled dietary conditions, our study shows that Lp(a) changes tended to be
greater in blacks compared to whites across all diets compared to baseline self-
selected diets, and among the three controlled diets. Our data therefore suggest
that there is indeed some inherent racial difference in the metabolism of Lp(a)
depending on macronutrient composition. We did not find gender differences in
dietary Lp(a) response which is consistent with previous observations [16].
Limitations of this study include the relatively short duration of dietary periods
as the effect of dietary interventions on Lp(a) could not be assessed in the long
Healthy Dietary Interventions and Lipoprotein (a)
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cannot exclude consumption of non-study food items as study adherence was
monitored by self-report. Moreover, we are missing data on apo(a) isoforms and
metabolism of Lp(a). Strengths are based on the crossover design, controlled
feeding, and isocaloric dietary protocol of this study which allow parsimonious
analysis with low risk of confounding. The risk of bias can be considered as low
because of high rates of adherence to and high follow-up after all three diets.
In conclusion, interventional DASH-type diets differing in macronutrient
content increased Lp(a) levels compared to baseline. Diets high in unsaturated fat
increased Lp(a) less than diets rich in carbohydrate or protein with larger
differences in blacks. Our results provide first systematic evidence for the changes
of Lp(a) as a result of macronutrient composition and suggest that substitutions
with dietary mono- and polyunsaturated fatty acids in healthy diets may be
preferable over protein or carbohydrates with regards to Lp(a).
Supporting Information
S1 Figure. Mean [95% CI] changes in plasma Lp(a) from baseline by diet after
adjustment for baseline Lp(a) levels. P-values for differences between races are
displayed. Study diets increased Lp(a) in blacks more than in whites with
significant differences after the Prot diet.
doi:10.1371/journal.pone.0114859.s001 (TIFF)
S2 Figure. Mean [95% CI] changes in plasma Lp(a) between study diets after
adjustment for baseline Lp(a). P-values for differences between diets and
between blacks and whites are displayed. Unsat Fat significantly reduced Lp(a)
compared to Prot or Carb. Blacks showed greater Lp(a) reductions when changing
from Prot to Unsat Fat as compared to whites.
doi:10.1371/journal.pone.0114859.s002 (TIFF)
S1 Table. Effect modification by sex for changes in Lp(a) concentration (mg/
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